Harald Prüss

Dr. Harald Prüss

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
Francesc GrausFrancesc Graus
Francesc Graus
AVAlberto Vogrig
Alberto Vogrig
SMSergio Muñiz-Castrillo
Sergio Muñiz-Castrillo
JAJean-Christophe G. Antoine
Jean-Christophe G. Antoine
VDVirginie Desestret
Virginie Desestret
JHJerome Honnorat
Jerome Honnorat
Objective The contemporary diagnosis of paraneoplastic neurologic syndromes (PNSs) requires an increasing understanding of their clinical, immunologic, and oncologic heterogeneity. The 2004 PNS criteria are partially outdated due to advances in PNS research in the last 16 years leading to the identification of new phenotypes and antibodies that have transformed the diagnostic approach to PNS. Here, we propose updated diagnostic criteria for PNS. Methods A panel of experts developed by consensus a modified set of diagnostic PNS criteria for clinical decision making and research purposes. The panel reappraised the 2004 criteria alongside new knowledge on PNS obtained from published and unpublished data generated by the different laboratories involved in the project. Results The panel proposed to substitute “classical syndromes” with the term “high-risk phenotypes” for cancer and introduce the concept of “intermediate-risk phenotypes.” The term “onconeural antibody” was replaced by “high risk” (>70% associated with cancer) and “intermediate risk” (30%–70% associated with cancer) antibodies. The panel classified 3 levels of evidence for PNS: definite, probable, and possible. Each level can be reached by using the PNS-Care Score, which combines clinical phenotype, antibody type, the presence or absence of cancer, and time of follow-up. With the exception of opsoclonus-myoclonus, the diagnosis of definite PNS requires the presence of high- or intermediate-risk antibodies. Specific recommendations for similar syndromes triggered by immune checkpoint inhibitors are also provided. Conclusions The proposed criteria and recommendations should be used to enhance the clinical care of patients with PNS and to encourage standardization of research initiatives addressing PNS.

16 July 2012 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
HPHarald Prüss
Harald Prüss
CFCarsten Finke
Carsten Finke
MHMarkus Höltje
Markus Höltje
JHJoerg Hofmann
Joerg Hofmann
CKChristine Klingbeil
Christine Klingbeil
KWKlaus‐Peter Wandinger
Klaus‐Peter Wandinger

13 August 2021 in Science
Verified
Journal Article
Open access
PDF file
MYMeng Yuan
Meng Yuan
DHDeli Huang
Deli Huang
CLChang-Chun D. Lee
Chang-Chun D. Lee
Nicholas WuNicholas Wu
Nicholas Wu
AJAbigail Jackson
Abigail Jackson
IWIan A. Wilson
Ian A. Wilson
Defenses against SARS-CoV-2 variants: Our key defense against the COVID-19 pandemic is neutralizing antibodies against the SARS-CoV-2 virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan et al . examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. —VV

1 November 2020 in Cell
Verified
Journal Article
Open access
JKJakob Kreye
Jakob Kreye
SRS. Momsen Reincke
S. Momsen Reincke
HKHans-Christian Kornau
Hans-Christian Kornau
ESElisa Sánchez-Sendin
Elisa Sánchez-Sendin
VCVictor M Corman
Victor M Corman
HPHarald Prüss
Harald Prüss
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an IC50 value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.

11 May 2021 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
HPHarald Prüss
Harald Prüss

20 August 2016 in Brain
Verified
Journal Article
Open access
PDF file
JKJakob Kreye
Jakob Kreye
NWNina Kerstin Wenke
Nina Kerstin Wenke
MCMariya Chayka
Mariya Chayka
JLJonas Leubner
Jonas Leubner
RMRajagopal Murugan
Rajagopal Murugan
HPHarald Prüss
Harald Prüss
See Zekeridou and Lennon (doi: 10.1093/aww213 ) for a scientific commentary on this article . Anti- N -methyl-D-aspartate receptor (NMDAR) encephalitis is a recently discovered autoimmune syndrome associated with psychosis, dyskinesias, and seizures. Little is known about the cerebrospinal fluid autoantibody repertoire. Antibodies against the NR1 subunit of the NMDAR are thought to be pathogenic; however, direct proof is lacking as previous experiments could not distinguish the contribution of further anti-neuronal antibodies. Using single cell cloning of full-length immunoglobulin heavy and light chain genes, we generated a panel of recombinant monoclonal NR1 antibodies from cerebrospinal fluid memory B cells and antibody secreting cells of NMDAR encephalitis patients. Cells typically carried somatically mutated immunoglobulin genes and had undergone class-switching to immunoglobulin G, clonally expanded cells carried identical somatic hypermutation patterns. A fraction of NR1 antibodies were non-mutated, thus resembling ‘naturally occurring antibodies’ and indicating that tolerance induction against NMDAR was incomplete and somatic hypermutation not essential for functional antibodies. However, only a small percentage of cerebrospinal fluid-derived antibodies reacted against NR1. Instead, nearly all further antibodies bound specifically to diverse brain-expressed epitopes including neuronal surfaces, suggesting that a broad repertoire of antibody-secreting cells enrich in the central nervous system during encephalitis. Our functional data using primary hippocampal neurons indicate that human cerebrospinal fluid-derived monoclonal NR1 antibodies alone are sufficient to cause neuronal surface receptor downregulation and subsequent impairment of NMDAR-mediated currents, thus providing ultimate proof of antibody pathogenicity. The observed formation of immunological memory might be relevant for clinical relapses.